Literature DB >> 17760691

Clostridium botulinum type A toxin for the treatment of upper face animation lines: an Iranian experience.

M Reza Farahvash1, Simin Arad.   

Abstract

The purpose of this study was to evaluate the treatment of vertical glabellar frown lines, frontal lines and crow's feet by means of direct injection of Dysport (Clostridium botulinum type A toxin - hemagglutinin complex) in Iranian patients. Dysport is one of the commercially available type A subtypes (Ipsen Ltd, Maidenhead Berkshire, UK). It is the one used most often in Iran. Botox, the other form of commercially available botulinum type A toxin, is used most often in the United States and Canada. Dysport is two to four times less effective, in similar unit doses, than Botox, which is why it is manufactured in larger vials (500-U vials for Dysport vs. 100-U vials for Botox). The authors have been using botulinum toxin type A in their practice for cosmetic purposes since 1995. An experience of over 1295 injections to the upper face animation (dynamic) lines in 108 patients is presented. This study included 108 patients and 208 injection sessions. We used Dysport containing 500 U toxin. Toxin was diluted with 2.5 mL of sterile normal saline and yielded 20 U for each 0.1 mL. A dose of 76 to 90 U was injected into each muscle. There were 95 women and 13 men in this study, ranging in age from 20 to 79 years. Doses ranged from 10 to 20 mL per injection, varying according to the severity of wrinkles, intensity of muscle contraction, and the mass of the muscle. The more bulky or greater intensity of muscle contraction, the higher the dose required to obtain good results. Therefore, the more bulky corrugator or frontalis muscle requires more than the thinner orbicularis. Dysport seemed to be a safe and effective alternative to Botox, giving good to excellent cosmetic results lasting at least 4 months in the majority of the patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17760691     DOI: 10.1111/j.1473-2165.2007.00325.x

Source DB:  PubMed          Journal:  J Cosmet Dermatol        ISSN: 1473-2130            Impact factor:   2.696


  4 in total

Review 1.  Onset and Duration of AbobotulinumtoxinA for Aesthetic Use in the Upper face: A Systematic Literature Review.

Authors:  Mark Nestor; Joel L Cohen; Marina Landau; Said Hilton; Andreas Nikolis; Syed Haq; Maurizio Viel; Bill Andriopoulos; Inna Prygova; Keith Foster; Alessio Redaelli; Philippe Picaut
Journal:  J Clin Aesthet Dermatol       Date:  2020-12-01

Review 2.  A Review of Complications Due to the Use of Botulinum Toxin A for Cosmetic Indications.

Authors:  Nitin Sethi; Sukhbir Singh; Koenraad DeBoulle; Eqram Rahman
Journal:  Aesthetic Plast Surg       Date:  2020-10-13       Impact factor: 2.326

Review 3.  Patient Satisfaction with AbobotulinumtoxinA for Aesthetic Use in the Upper Face: A Systematic Literature Review and Post-hoc Analysis of the APPEAL Study.

Authors:  Riekie Smit; Elena Gubanova; Joely Kaufman; Marina Landau; Beatriz Molina; Bill Andriopoulos; Pascal Maisonobe; Inna Prygova; Alessio Redaelli
Journal:  J Clin Aesthet Dermatol       Date:  2021-02-01

4.  Triple-Blind, Prospective, Internally Controlled Comparative Study Between AbobotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Facial Rhytids.

Authors:  Ramtin Kassir; Aparanjita Kolluru; Martin Kassir
Journal:  Dermatol Ther (Heidelb)       Date:  2013-08-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.